Trial Profile
An Open-Label, Multicenter, Dose-Escalation Phase Ib Study With Expansion Phase to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Emactuzumab and RO7009789 Administered in Combination in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Emactuzumab (Primary) ; Selicrelumab (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 01 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2017 Planned End Date changed from 1 Jul 2018 to 28 Jul 2018.